Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.

Drug Delivery Devices and Therapeutic Systems examines the current technology and innovations moving drug delivery systems (DDS) forward. The book provides an overview on the therapeutic use of drug delivery devices, including design, applications, and a description of the design of each device. While other books focus on the therapy, the primary emphasis in this book is on current technologies for DDS applications, including microfluidics, nanotechnology, biodegradable hydrogel and microneedles, with a special emphasis on wearable DDS. As part of the Developments in Biomedical Engineering and Bioelectronics series, this book is written by experts in the field and informed with information directly from manufacturers. Pharmaceutical scientists, medical researchers, biomedical engineers and clinical professionals will find this an essential reference. - Provides essential information on the most recent drug delivery systems available - Explains current technology and its applications to drug delivery - Contains contributions from biomedical engineers, pharmaceutical scientists and manufacturers

This issue of Surgical Oncology Clinics of North America, guest edited by Dr. Mark Krasna, is devoted to Lung Cancer. Dr. Krasna has assembled expert authors to review the following topics: Epidemiology for Lung Cancer; Screening for Lung Cancer; Pathology for Lung Cancer; Treatment of Patients with Oligometastatic Disease for NSCLC; SBRT/Ablative Therapies for NSCLC; Mediastinal Staging for Lung Cancer; VATS Lobectomy for NSCLC; Robotic Lung Resection for NSCLC; Pneumonectomy for NSCLC; Bronchoscopy-Diagnostic and Therapeutic for NSCLC; Neoadjuvant Therapy for Lung Cancer; Molecular/Targeted Therapy for Lung Cancer; Adjuvant Therapy for Stage 1and 2 NSCLC, and more!

MTOR Inhibitors—Advances in Research and Application: 2013 Edition is a ScholarlyPaper™ that delivers timely, authoritative, and intensively focused information about ZZZAdditional Research in a compact format. The editors have built MTOR Inhibitors—Advances in Research and Application: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about ZZZAdditional Research in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of MTOR Inhibitors—Advances in Research and Application: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

Clinical Application of Repurposed Drugs, Volume 207 in the Progress in Molecular Biology and Translational Science series, highlights new advances in the field, with this new volume presenting interesting chapters on Drug repurposing for viral disease, Drug repurposing for bacterial infections, Drug repurposing for parasitic protozoan diseases, Drug repurposing for fungal infections, Drug repurposing for treating anxiety and depression, Drug repurposing for personalized medicine, Drug repurposing for cancer, Drug Repurposing: A multi targeted approach to treat cardiac disease from existing classical drugs to modern drug discovery, and much more. Additional chapters cover Drug repurposing in MASLD and MASH-cirrhosis: targets and treatment approaches based on pathways analysis, Drug repurposing for respiratory infections, Drug repurposing for rare disease, Drug repurposing for neurological disorders, Drug repurposing for metabolic disorders: scientific, technological and economic issues, Drug repurposing for regenerative medicine and cosmetics: scientific, technological and economic issues, and Exploring Cutting-Edge Omics-Driven Strategies for Drug Repurposing – An Insight into the Tools of the Trade. - Provides the authority and expertise of leading contributors from an international board of authors - Presents the latest release in the Progress in Molecular Biology and Translational Science series - Includes the latest information on Clinical Applications of Repurposed Drugs

Radiation Medicine Rounds is a trinary, hard cover periodical designed to provide an up-to-date review of a dedicated radiation medicine topic of interest to clinicians and scientists who are involved in the care of patients receiving radiotherapy. It is intended to serve as both a reference and instructional tool for students, housestaff, fellows, practicing clinicians, medical physicists, cancer biologists, radiobiologists, and interdisciplinary colleagues throughout the oncology spectrum. This issue of Radiation Medicine Rounds discusses the more salient topics surrounding the role of radiation therapy for malignant gliomas. The specialty of radiation therapy has increased in complexity over the years, yet as technology improves, the goal of improving outcomes while decreasing toxicity remains critical. Malignant gliomas remain among the most devastating of all malignancies, yet as conventional treatments (surgery, radiation, and chemotherapy) have become optimized overall survival has improved. The underlying molecular and genetic mechanisms of these tumors are becoming better understood, with one of the most important realizations being that histopathologically identical malignant gliomas often demonstrate very distinct clinical behaviors. Malignant Gliomas provides the practitioner with a current overview of best practices, recent research, and future directions in the management of this complex and challenging cancer. "

Hematologic malignancies (HMs) represent a group of hematologic cancers originating from bone marrow or lymphoid organs. Currently, leukaemia, lymphoma, and multiple myeloma are the most common HMs. Conventional treatments for HMs include bone marrow transplantation, radiotherapy, chemotherapy, and immunotherapy. Despite the significant achievements obtained over the past decade in the drug therapy of HMs, tumor metastasis and relapse in patients often occurred after an initial response, indicating the generation of drug resistance to current therapies. Moreover, many clinically used therapeutic drugs are often associated with dose-related side effects and a lack of specificity to tumor tissues. The tumor microenvironment (TME) in HMs consists of a complicated network of cellular interactions and signaling cross-talking within the bone marrow cavity, and it plays an essential role in the progression and metastasis of HM. Furthermore, the TME in HMs has formed physiologic barriers such as immunosuppressive microenvironment, upregulated anti-apoptotic system, drug resistance, etc. to facilitate drug resistance and relapse of HMs. It has become widely accepted that effective treatment against HMs may require targeting both the cancer cell and TME.

This book discusses the various modes and methods of nano-based drug delivery in different types of cancers such as colon, breast, cervical, ovarian, and lung cancer. It reviews the significance of nano drug delivery in cancer therapy, the application of nanoparticles in overcoming drug resistance, targeted therapy, and immunotherapy. The book also covers topics related to the synthesis of different types, shapes, and sizes of nanocarriers using synthetic and biological approaches. Further, a chapter explores the synthesis of nanocarriers loaded with anti-cancer drugs by using functionalization or conjugations and encapsulation methods. The book also examines the nanocarriers as delivery vehicles for chemotherapeutic agents against cancers using in vitro and animal models of cancers, preclinical trials for efficacy, and safety profiling of nanocarriers. Finally, future trends and innovation in nano drug delivery for cancer therapy, application of siRNA (nanoparticle-based RNA) therapy, ultrasound-linked nano-cancer therapeutics, and application of exosome-based cancer therapy topics are discussed. Towards the end, the book examines the limitations of nanocarriers, including the cell and tissue toxicity, genotoxicity, and scale-up of nanomaterials, health and environmental hazards associated with nanoformulation synthesis, respiratory diseases, government regulations, and ethical issues.

Over the past few decades, lymphoma patient outcomes have improved as a result of multidrug chemotherapy and radiation therapy, intensification of treatment, improvement in supportive care, and better imaging and staging systems. Even more recently, there has been tremendous progress in the understanding of cancer cell biology and its microenvironment which has resulted in the development of biologic agents, also called "target" therapies. These therapies are more specific in targeting cancer cells either directly or via enhancement of the immune system. Many clinical studies have focused on biological agents in combination with traditional chemotherapy with the goal of improved outcomes, or reduced acute long term complications that are associated with lymphoma therapy. This volume will review different classes of "target" drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical response of those agents, but will also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those drugs. Contributors will discuss what is currently known about mechanisms of tumor-related or host-related resistance, and how to overcome this resistance. This understanding is crucial given the dismal outcomes of patients with relapsed or refractory lymphomas. The book provides a unique opportunity to review and reflect on the recent successes and pitfalls of the modern lymphoma therapy era.